Skip to main content

Advertisement

SpringerLink
Log in

Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab

  • Therapy in Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Anti-programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab are becoming increasingly important in the treatment of melanoma and non-small cell lung cancer. These agents are known to induce many immune-related adverse events, but rapid-onset nephritis and immune-related hyponatremia have not been described to date. We describe the case of an adult patient who developed severe hyponatremia and rapid-onset nephritis following the first infusion of nivolumab for metastatic melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.

    Article  CAS  PubMed  Google Scholar 

  3. Postow MA, Chesney J, Pavlick AC, Robert C, Grossman K, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.

    Article  PubMed  Google Scholar 

  4. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84.

    Article  CAS  PubMed  Google Scholar 

  5. Opdivo [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2016.

  6. Nivolumab Clinical Trials. U.S. National Library of Medicine. 2013. https://clinicaltrials.gov/ct2/results?term=nivolumab&Search=Search. Accessed 21 Sept 2015.

  7. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–92.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Barbee MS, Ogunniyi A, Horvat TZ, Dang T. Current status and future directions of the immune checkpoint inhibitors ipilmumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015;49(8):907–37.

    Article  CAS  PubMed  Google Scholar 

  9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Wyoming School of Pharmacy, Health Sciences Center, Room 292, 1000 E. University Ave., Dept. 3375, Laramie, WY, 82071, USA

    Jeremy W. Vandiver & Cara Harshberger

  2. Swedish Family Medicine Residency Program, Littleton, CO, USA

    Jeremy W. Vandiver & Zachary Singer

Authors
  1. Jeremy W. Vandiver
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zachary Singer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cara Harshberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeremy W. Vandiver.

Ethics declarations

Funding

None.

Conflict of Interest

JWV, ZS and CH declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vandiver, J.W., Singer, Z. & Harshberger, C. Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. Targ Oncol 11, 553–556 (2016). https://doi.org/10.1007/s11523-016-0426-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-016-0426-9

Keywords

Search

Navigation